Using a technique developed at Vanderbilt University Medical Center, researchers identified antibodies that are excellent leads as potential therapies for human parainfluenza virus 3, a leading cause of acute and potentially fatal respiratory illness.

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.

Vanderbilt's James Crowe Jr., MD, was among those to receive 2023 Advocacy Awards from Research!America at the biomedical research advocacy organization’s annual awards program in Washington, D.C.

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.